Skip to main content

Table 2 Baseline characteristics and treatment administered. Only patients with genotyping and PC1/2 results are presented

From: Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatmentsa WWARN individual patient data meta-analysis

  Asia Africa
N Median (range) or N (%) N N (%) or median (range)
Age (years) 2630 21 [0.1–70] 204 4.7 [0.7–29]
 < 1 year   8 [0]   11 [5]
 1–4 years   185 [7]   98 [48]
 5–11 years   407 [15]   82 [40]
 12+ years   2030 [77]   13 [6]
Parasitemia (microliter) 2631 97,214 [455–2,409,008] 204 53,507 [2240 - 605,329]
Temperature (C) 1658 38.2 [34.1–41.5] 204 37.6 [34.7–40.8]
Hemoglobin (g/dL) 770 13.1 [2.1–19.3] 26 10.8 [6.3–14.2]
Hematocrit (%) 1542 40 [12–55] 140 31 [21–44]
Artemisinin derivative: total 3 days dose (mg/kg)
AL 0   80 9.3 [5.2–16.0]
AS 433 8.3 [1.0–49.7] 0  
AS + ACT1 1638 8.3 [0.5–28.9] 83 11.8 [4.7–15]
ASAQ 0   41 13.0 [8.6–16.7]
ASMQ 81 8.0 [3.8–16.1] 0  
DHAPIP 430 6.7 [3.0–17.8] 0  
  1. 1Artesunate was given in the first 3 days alone, followed by ACT
\